Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sonoma Pharmaceuticals (SNOA) EBT (2016 - 2025)

Sonoma Pharmaceuticals has reported EBT over the past 16 years, most recently at -$949000.0 for Q4 2025.

  • For Q4 2025, EBT fell 3.26% year-over-year to -$949000.0; the TTM value through Dec 2025 reached -$3.4 million, up 7.7%, while the annual FY2025 figure was -$2.9 million, 42.22% up from the prior year.
  • EBT for Q4 2025 was -$949000.0 at Sonoma Pharmaceuticals, down from -$731000.0 in the prior quarter.
  • Over five years, EBT peaked at -$95000.0 in Q3 2021 and troughed at -$3.3 million in Q1 2022.
  • A 5-year average of -$1.2 million and a median of -$973000.0 in 2024 define the central range for EBT.
  • Biggest five-year swings in EBT: plummeted 865.26% in 2022 and later surged 64.33% in 2024.
  • Year by year, EBT stood at -$944000.0 in 2021, then plummeted by 101.8% to -$1.9 million in 2022, then soared by 51.55% to -$923000.0 in 2023, then grew by 0.43% to -$919000.0 in 2024, then fell by 3.26% to -$949000.0 in 2025.
  • Business Quant data shows EBT for SNOA at -$949000.0 in Q4 2025, -$731000.0 in Q3 2025, and -$1.2 million in Q2 2025.